Опыт использования анти-VEGF-npempara в лечении посттромботической неоваскулярной глаукомы.
Аннотация
Об авторе
С. Н. ТульцеваРоссия
Список литературы
1. Качанов, А. Б. Диодлазерная транссклеральная контактная циклокоагуляция в лечении различных форм глауком и офтальмогипертензий (экспериментально-клиническое исследование) : автореф. дис. ... канд. мед. наук/А. Б. Качанов. - СПб., 1998. - 30 с.
2. Aiello, L. P. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders / L. P. Aiello [et al]//N. Engl. J. Med. -1994. - № 331. - Р. 1480-1487.
3. Bhagat, N. Central retinal vein occlusion : review of management/ N. Bhagat [et al] // Eur. J. Ophthalmol. - 1999. - № 9 (3). - Р. 165-180.
4. Central Vein Occlusion Study Group : Baseline and early natural history report // The Central Vein Occlusion Study // Arch. Ophthalmol. - 1993. - № 111. - Р. 1087.
5. Chilov, M. N. Bevacizumab (Avastin) for the treatment of neovascular glaucoma / M. N. Chilov, J. R. Grigg, T. J. Playfair // Clin. Exp. Ophthalmol. - 2007. - № 35. - Р. 494-496.
6. Ciftci, S. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma /S. Ciftci [et al] //Eur. J. Ophthalmol. - 2009. - № 19 (6). - Р. 1028-1033.
7. Davidorf, F. H. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection /F. H. Davidorf [et al] //Retina. - 2006. - № 26. - Р. 354-356.
8. Ehlers, J. P. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma / J. P. Ehlers [et al] //Retina. - 2008. - № 28 (5). - Р. 696-702.
9. Fong, A. W. Management of neovascular glaucoma with trans-scleral cyclophotocoagulation with diode laser alone versus combination trans-scleral cyclophotocoagulation with diode laser and intravitreal bevacizumab/A. W. Fong [et al] // Clin Experiment Ophthalmol. - 2010. - oct 25. - (doi: 10.1111/j.1442-9071.2010.02449.x. [Epub ahead of print]).
10. Funatsu, H. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients / H. Funatsu [et al] // Graefes. Arch. Clin. Exp. Ophthalmol. - 2005. - № 243 (1). - Р. 3-8.
11. Funk, M. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab / M. Funk [et al] //Invest. Ophthalmol. Vis. Sci. - 2009. - № 50 (3). - Р. 1025-1032.
12. Gheith, M. E. Role of intravitreal bevacizumab in neovascular glaucoma / M. E. Gheith [et al] // J. Ocul. Pharmacol. Ther. - 2007. - № 23. - Р. 487-491.
13. Ghosh, S. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma / S. Ghosh [et al] // Clin. Experiment. Ophthalmol. - 2010. - № 38 (4). - Р. 353-357.
14. Gregori, N. Z. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion / N. Z. Gregori // Retina. - 2009. - № 29 (7). - Р. 913-925.
15. Hasanreisoglu, M. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma / M. Hasanreisoglu [et al] // Eur. J. Ophthalmol. - 2009. - № 19 (4). - Р. 607-612.
16. Hayreh, S. S. Prevalent misconceptions about acute retinal vascular occlusive disorders / S. S. Hayreh // Prog. Retin. Eye Res. - 2005. - № 24 (4). - Р. 493-519.
17. Iliev, M. E. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma / M. E. Iliev [et al] // Am. J. Ophthalmol. - 2006. - № 142. - Р. 1054-1056.
18. Kahook, M. Y. Intravitreal bevacizumab in a patient with neovascular glaucoma / M. Y. Kahook [et al] // Ophthalmic. Surg. Lasers. Imaging. - 2006. - № 37. - Р. 144-146.
19. Mason, J. O. Regression of neovascular iris vessels by intravitreal injection of bevacizumab / J. O. Mason [et al] // Retina. - 2006. - № 26. - Р. 839-841.
20. Moraczewski, A. L. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab /A. L. Moraczewski [et al] // Br. J. Ophthalmol. - 2009. - № 93 (5). - Р. 589-593.
21. Noma, H. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion / H. Noma [et al] // Eye. - 2008. - № 22 (1). - Р. 42-48.
22. Noma, H. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6 / H. Noma [et al] //Am. J. Ophthalmol. - 2005. - № 140 (2). - Р. 256-261.
23. Patel, J. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema : implications for structural differences in macular profiles / J. Patel [et al] // Exp. Eye Res. - 2006. - № 82 (5). - Р. 798-806.
24. Paula, J. S. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma / J. S. Paula, R. Jorge, R. A. Costa // Acta. Ophthalmol. Scand. - 2006. - № 84. - Р. 556-557.
25. Pe'er, J. Vascular endothelial growth factor upregulation in human central retinal vein occlusion / J. Pe'er [et al] // Ophthalmology. - 1998. - № 105 (3). - Р. 412-416.
26. Prager, F. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial / F. Prager [et al] // Br. J. Ophthalmol. - 2009. - № 93 (4). - Р. 452-456.
27. Rosenfeld, P. J. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study /P. J. Rosenfeld [et al] // Ophthalmology. - 2005. - № 112 (6). - Р. 1035-1047.
28. Schields, М. В. Textbook of glaucoma / M. B. Schields. - 1997. - P. 269-286.
29. Tan, A. M. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma /A. M. Tan [et al] // Clin. Experiment. Ophthalmol. - 2010. - № 38 (3). - Р. 266-272.
30. The Central Vein Occlusion Study Group : A randomized clinical trial ofearly panretinal photocoagulation for ischemic central vein occlusion. The central vein occlusion study group N report // Ophthalmology. - 1995. - № 102 (10). - Р. 1434-1444.
31. The Central Vein Occlusion Study Group : Natural history and clinical management of central retinal vein occlusion //Arch. Ophthalmol. - 1997. - № 115 (4). - Р. 486-491.
32. Wakabayashi, T. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41, consecutive cases / T. Wakabayashi [et al] // Ophthalmology. - 2008. - № 115 (9). - Р. 1571-1580.
33. Weiss, D. I. Neovascular gluacoma complicating carotid-cavernous fistula / D. I. Weiss [et al] // Arch. Ophthalmol. - 1963. - № 69. - Р. 304-307.
34. Williamson, T. H. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion : a population controlled study / T. H. Williamson, A. Rumley, G. D. Lowe // Br. J. Ophthalmol. - 1996. - № 80 (3). - Р. 203-208.
Рецензия
Для цитирования:
Тульцева С.Н. Опыт использования анти-VEGF-npempara в лечении посттромботической неоваскулярной глаукомы. Регионарное кровообращение и микроциркуляция. 2010;9(4):53-57. https://doi.org/10.24884/1682-6655-2010-9-4-53-57